Murray Arons, MD
Pulmonary Disease · Nashville, TNNPI 1801894142
Payments from drug & device makers
Across 319 payments — averaging $45.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Actelion Pharmaceuticals US, Inc.$2K
- GSK$793
- Insmed, Inc.$614
- Boehringer Ingelheim$606
- Inspire Medical Systems, Inc.$331
- plus $2K from 34 others
What the payments were for
- Travel & lodging$9787%
- Food & beverage$6,35044%
- Education$7,21650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $8,007 |
| Actelion Pharmaceuticals US, Inc. | 89 | $1,734 |
| GSK | 45 | $793 |
| Insmed, Inc. | 23 | $614 |
| Boehringer Ingelheim | 28 | $606 |
| Inspire Medical Systems, Inc. | 5 | $331 |
| Jazz Pharmaceuticals Inc. | 11 | $290 |
| Grifols USA, LLC | 13 | $273 |
| Merck | 5 | $219 |
| AstraZeneca | 13 | $205 |
| Harmony Biosciences LLC | 8 | $164 |
| Sanofi | 6 | $123 |
| Medtronic | 2 | $105 |
| Novartis | 7 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $97 |
| United Therapeutics Corporation | 4 | $88 |
| Bayer | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| Genentech USA, Inc. | 5 | $75 |
| Portola Pharmaceuticals, LLC | 4 | $65 |
| Philips North America LLC | 4 | $53 |
| Baxter Healthcare | 2 | $50 |
| Eisai Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Mylan Specialty L.p. | 2 | $28 |
| Johnson & Johnson | 1 | $27 |
| Fisher & Paykel Healthcare Inc | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| ZOLL Respicardia, Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $20 |
| Inari Medical, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Sandoz | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Amgen | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,929
- Inspire$138
- WINREVAIR$123
- UPTRAVI$123
How this compares
$14,545 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 20 | $244,550 |
| OfevNintedanib Esylate | 15 | $192,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $41,728 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $32,975 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $25,666 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $19,590 |
| EliquisApixaban | 11 | $10,973 |
| XareltoRivaroxaban | 19 | $10,140 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $4,906 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,992 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,770 |
| Azithromycin | 29 | $594 |
| Modafinil | 16 | $351 |
| Trazodone Hcl | 77 | $300 |
| Montelukast Sodium | 21 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,734 | $244,55020 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $606 | $217,92358 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $793 | $102,190183 claims |
| PfizerEliquis | $14 | $10,97311 claims |
| Johnson & JohnsonXarelto | $27 | $10,14019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Fabien MaldonadoNashville$2.5M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Otis RickmanNashville$426K
- Jonathan KropskiNashville$419K
- Justin HewlettNashville$388K
- Susan GarwoodNashville$351K
- Margaret SalisburyNashville$345K
- Joao DeandradeNashville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.